Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Articles online first > Minerva Ginecologica 2020 Mar 17



Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Ginecologica 2020 Mar 17

DOI: 10.23736/S0026-4784.20.04508-6


lingua: Inglese

A review of the use of hormonal contraception in women with cardiovascular disease complications and risk factors. A systematic review

Tehila FEINBERG 1, Michelle ROUGERIE 2, Yehuda S. DAHAN 3, Michael H. DAHAN 2

1 Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel; 2 Department of Obstetrics and Gynecology, McGill University Health Center, McGill University, Montreal, Canada; 3 High School Student Performing a Research Rotation at McGill University, Montreal, Canada


INTRODUCTION: The Centers for Disease Control and Prevention (CDC) developed a point form guideline for the use of oral contraceptives in women with co-existing medical conditions. Although this acts as a guide, it leaves the clinician without an understanding of why they are doing what they are doing.
EVIDENCE ACQUISITION: In this article, which is one of two articles addressing co-existing medical condition and oral contraceptive use, an update of the scientific knowledge is provided.
EVIDENCE SYNTHESIS: The explanation of the guidelines are to be used as a supplement for those who desire more information than is found in the CDC guidelines and in general a review for clinicians dealing with women desiring hormonal contraception.
CONCLUSIONS: The development of lower dose contraceptive pills as well as the increased incidence of comorbid conditions, such as metabolic syndrome, in younger women seeking contraception has brought along new research and new evidence to guide clinicians in the prescription of these medications.

KEY WORDS: Oral contraceptives; OCP; Co-morbidity; Cardiovascular disease

inizio pagina